Micofenolato De Mofetil Tecnigen (Mycophenolate Mofetil)

Mycophenolate Mofetil is converted inside cells to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition stops the synthesis of guanosine nucleotides needed for DNA replication, thereby suppressing the proliferation of activated T‑ and B‑lymphocytes that drive transplant rejection.

The dose of Micofenolato De Mofetil Tecnigen is individualized by the prescribing clinician. Factors such as the type of organ transplanted, patient body weight, renal and hepatic function, and concomitant immunosuppressive therapy influence the final dosing regimen.

Safety data are limited. Mycophenolate Mofetil can cause fetal harm, so it is generally contraindicated in pregnancy unless no suitable alternatives exist and the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—selective inhibition of lymphocyte proliferation—resulting in a distinct side‑effect profile. It is often used in combination with calcineurin inhibitors to achieve synergistic immunosuppression while potentially allowing lower doses of each agent.

Store the product at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging until use.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. It should be swallowed whole and not crushed or chewed unless specifically instructed.

Serious risks include profound leukopenia or neutropenia, which can predispose to severe infections, hepatotoxicity, and an increased incidence of certain malignancies such as lymphoproliferative disorders. Patients should be monitored regularly for blood‑cell counts and liver function.

Patients with known hypersensitivity to Mycophenolate Mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals with active, uncontrolled infections and should be used with caution in those with severe renal or hepatic impairment.